191 related articles for article (PubMed ID: 37024879)
1. miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma.
Papadimitriou MA; Soureas K; Papanota AM; Tsiakanikas P; Adamopoulos PG; Ntanasis-Stathopoulos I; Malandrakis P; Gavriatopoulou M; Sideris DC; Kastritis E; Avgeris M; Dimopoulos MA; Terpos E; Scorilas A
J Transl Med; 2023 Apr; 21(1):245. PubMed ID: 37024879
[TBL] [Abstract][Full Text] [Related]
2. miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome.
Papadimitriou MA; Papanota AM; Adamopoulos PG; Pilala KM; Liacos CI; Malandrakis P; Mavrianou-Koutsoukou N; Patseas D; Eleutherakis-Papaiakovou E; Gavriatopoulou M; Kastritis E; Avgeris M; Dimopoulos MA; Terpos E; Scorilas A
Br J Cancer; 2022 Jan; 126(1):79-90. PubMed ID: 34718359
[TBL] [Abstract][Full Text] [Related]
3. Small RNA-seq and clinical evaluation of tRNA-derived fragments in multiple myeloma: Loss of mitochondrial i-tRF
Soureas K; Papadimitriou MA; Malandrakis P; Papanota AM; Adamopoulos PG; Ntanasis-Stathopoulos I; Liacos CI; Gavriatopoulou M; Sideris DC; Kastritis E; Dimopoulos MA; Scorilas A; Terpos E; Avgeris M
Br J Haematol; 2024 May; 204(5):1790-1800. PubMed ID: 38414235
[TBL] [Abstract][Full Text] [Related]
4. A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma.
Papanota AM; Karousi P; Kontos CK; Artemaki PI; Liacos CI; Papadimitriou MA; Bagratuni T; Eleutherakis-Papaiakovou E; Malandrakis P; Ntanasis-Stathopoulos I; Gavriatopoulou M; Kastritis E; Avgeris M; Dimopoulos MA; Scorilas A; Terpos E
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884950
[TBL] [Abstract][Full Text] [Related]
5. miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patients.
Panoutsopoulou K; Avgeris M; Magkou P; Mavridis K; Dreyer T; Dorn J; Obermayr E; Reinthaller A; Michaelidou K; Mahner S; Vergote I; Loverix L; Braicu I; Sehouli J; Zeillinger R; Magdolen V; Scorilas A
Int J Cancer; 2020 Dec; 147(12):3560-3573. PubMed ID: 32621752
[TBL] [Abstract][Full Text] [Related]
6. Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study.
Goldsmith SR; Fiala MA; Dukeman J; Ghobadi A; Stockerl-Goldstein K; Schroeder MA; Tomasson M; Wildes TM; Vij R
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):285-289. PubMed ID: 30792096
[TBL] [Abstract][Full Text] [Related]
7. Repression of miR-146a in predicting poor treatment outcome in triple-negative breast cancer.
Panoutsopoulou K; Liu Y; Avgeris M; Dreyer T; Dorn J; Magdolen V; Scorilas A
Clin Biochem; 2023 Apr; 114():43-51. PubMed ID: 36502883
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive small RNA-sequencing of primary myeloma cells identifies miR-105-5p as a predictor of patient survival.
Roseth Aass K; Nedal TMV; Anshushaug Bouma S; Tryggestad SS; Haukås E; Slørdahl TS; Waage A; Standal T; Mjelle R
Br J Cancer; 2023 Feb; 128(4):656-664. PubMed ID: 36446884
[TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNA ANRIL and its target microRNAs (microRNA-34a, microRNA-125a and microRNA-186) relate to risk stratification and prognosis in multiple myeloma.
Yin Y; Yang W; Zhang L; Liu K; Luo Z
Hematology; 2021 Dec; 26(1):160-169. PubMed ID: 33528317
[TBL] [Abstract][Full Text] [Related]
10. Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma.
Hao M; Zang M; Wendlandt E; Xu Y; An G; Gong D; Li F; Qi F; Zhang Y; Yang Y; Zhan F; Qiu L
Int J Cancer; 2015 Apr; 136(8):1835-44. PubMed ID: 25220540
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A
Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841
[No Abstract] [Full Text] [Related]
12. The diagnostic and prognostic values of circulating miRNA-1246 in multiple myeloma.
Zhao G; Jing X; Li Z; Wu X; Gao Z; Ma R
Hematology; 2022 Dec; 27(1):778-784. PubMed ID: 35793786
[TBL] [Abstract][Full Text] [Related]
13. miRNA and cancer; computational and experimental approaches.
Tutar Y
Curr Pharm Biotechnol; 2014; 15(5):429. PubMed ID: 25189575
[TBL] [Abstract][Full Text] [Related]
14. Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression.
Wang W; Corrigan-Cummins M; Barber EA; Saleh LM; Zingone A; Ghafoor A; Costello R; Zhang Y; Kurlander RJ; Korde N; Roccaro AM; Ghobrial IM; Landgren O; Calvo KR
J Mol Diagn; 2015 Nov; 17(6):669-78. PubMed ID: 26433312
[TBL] [Abstract][Full Text] [Related]
15. Single-cell RNA-seq reveals clonal diversity and prognostic genes of relapsed multiple myeloma.
He H; Li Z; Lu J; Qiang W; Jiang S; Xu Y; Fu W; Zhai X; Zhou L; Qian M; Du J
Clin Transl Med; 2022 Mar; 12(3):e757. PubMed ID: 35297204
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-146b overexpression associates with deteriorated clinical characteristics, increased International Staging System stage, cacoethic chromosome abnormality, and unfavorable prognosis in multiple myeloma patients.
Bao Y; Wei M; Ji X
J Clin Lab Anal; 2020 May; 34(5):e23168. PubMed ID: 31908003
[TBL] [Abstract][Full Text] [Related]
17. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis.
Pichiorri F; Suh SS; Ladetto M; Kuehl M; Palumbo T; Drandi D; Taccioli C; Zanesi N; Alder H; Hagan JP; Munker R; Volinia S; Boccadoro M; Garzon R; Palumbo A; Aqeilan RI; Croce CM
Proc Natl Acad Sci U S A; 2008 Sep; 105(35):12885-90. PubMed ID: 18728182
[TBL] [Abstract][Full Text] [Related]
18. miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study.
Panoutsopoulou K; Avgeris M; Mavridis K; Dreyer T; Dorn J; Obermayr E; Reinthaller A; Michaelidou K; Mahner S; Vergote I; Vanderstichele A; Braicu I; Sehouli J; Zeillinger R; Magdolen V; Scorilas A
Carcinogenesis; 2020 Jun; 41(4):442-451. PubMed ID: 31586203
[TBL] [Abstract][Full Text] [Related]
19. Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis.
Hao M; Zang M; Zhao L; Deng S; Xu Y; Qi F; An G; Qin Y; Sui W; Li F; Yang W; Li Z; Yi S; Zou D; Zhan F; Qiu L
Oncotarget; 2016 Apr; 7(15):19589-600. PubMed ID: 26995755
[TBL] [Abstract][Full Text] [Related]
20. Expression of Peripheral Blood miRNA-720 and miRNA-1246 Can Be Used as a Predictor for Outcome in Multiple Myeloma Patients.
Ren Y; Li X; Wang W; He W; Wang J; Wang Y
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17(7):415-423. PubMed ID: 28601493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
